Go Back   HER2 Support Group Forums > Breast Cancer News
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 05-31-2011, 08:19 PM   #1
Senior Member
Jackie07's Avatar
Join Date: Jan 2008
Location: "Love never fails."
Posts: 5,808
Bone modifying agents - Denosumab now added

The Use of Bone-Modifying Agents

Treatment-related bone loss and the subsequent increase in fracture risk is an increasingly important concern for patients with metastatic breast cancer (MBC) receiving hormonal agents or chemotherapy. In postmenopausal women, the natural and progressive loss of bone mineral density associated with aging can be accelerated by the administration of an aromatase inhibitor (AI).[Eastell 2008; McCloskey 2007; LÝnning 2005; Coombes 2004]

Recently updated results of the landmark ATAC trial demonstrated an annual fracture rate of 2.93% in postmenopausal women receiving an AI for 5 years.[ATAC Trialistsí] Although this trial was performed in the adjuvant setting, the results show a substantial degree of bone loss that could also be seen in the metastatic setting among patients on prolonged AI therapy. In premenopausal patients with breast cancer, chemotherapy-induced premature ovarian failure or treatments aimed at ovarian function inhibition can lead to sudden and substantial bone density loss.[Shapiro 2001]

Medical oncologists treating breast cancer patients have therefore recently taken a more proactive role in the evaluation and management of treatment-related bone loss in these women. In addition to the impact of treatments on bone health, the skeleton is one of the main sites of metastasis for women with MBC that may lead to pain and pathological fractures.[Coleman 2001]
Bisphosphonates are bone-modifying agents that prevent the loss of bone mass. There is an expanding role for bisphosphonates in the therapy of breast cancer patients. Traditionally, these agents were administered for the prevention of skeletal events in patients with osseous metastases; however, recently they have been evaluated as part of the management strategy to prevent further bone loss, particularly in the adjuvant setting.

Results from the ABCSG-12 bone density subprotocol and the Z-FAST trial clearly demonstrated the effectiveness of the bisphosphonate zoledronic acid in preserving bone mineral density in pre- and postmenopausal women on hormonal manipulation, respectively.[Gnant 2008; Brufsky 2009b] Although both trials focus on women receiving adjuvant treatments, it is reasonable to expect bisphosphonates to also reduce bone loss in patients with MBC; however, this has not been tested prospectively. Although not yet confirmed, there is a growing body of data that suggest that bisphosphonates also improve breast cancer outcomes when given in combination with adjuvant endocrine therapy in both premenopausal and postmenopausal women.[Gnant 2009]

It is still unclear what the optimal bisphosphonate for preventing bone loss should be considering that both oral and intravenous agents have been tested in different doses and schedules. Trials have evaluated both short- and long-term therapy, raising uncertainty about the most advantageous duration of treatment as well. Evidence also suggests that some bone loss is recoverable after cessation of hormonal manipulation or chemotherapy, raising the question of the best time to institute these agents.

Denosumab, a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), was approved by the US Food and Drug Administration in November 2010 for the prevention of skeletal-related events in patients with bone metastases from solid tumors. This approval was based on 3 pivotal studies of denosumab vs zoledronic acid. In these studies, denosumab showed superior efficacy when compared head to head with zoledronic acid in breast cancer and castrate-resistant prostate cancer and was noninferior (trend toward superiority) for preventing/delaying skeletal-related events in solid tumors.[Stopeck 2009; Fizazi 2011; Henry 2009] Subsequently, the National Comprehensive Cancer Network added denosumab to the list of agents recommended (along with zoledronic acid and pamidronate) to help prevent skeletal-related events in selected patients with bone metastases.[NCCN 2011]

In February 2011, the American Society of Clinical Oncology updated the 2003 version of its Clinical Practice Guideline for the use of bone-modifying agents.[Van Poznak 2011]In patients with metastatic breast cancer who have evidence of bone metastases, denosumab is now listed as a recommended bone-modifying agent to be administered at a dose of 120 mg subcutaneously every 4 weeks. The guideline recommends careful monitoring for hypocalcemia in patients with creatinine clearance < 30 mg/mL or in those patients receiving dialysis. The package insert of zoledronic acid now provides guidance for dosing when a patientís baseline serum creatinine clearance is ≥ 30 and < 60 mg/mL. The updated guideline also recommends that before receiving a bone-modifying agent, a patient should have a dental examination and/or any necessary preventive dentistry.

©2003-2011 Clinical Care Options, LLC. All Rights Reserved.

Erythema Nodosum 85
Life-long Central Neurocytoma 4x5x6.5 cm 23 hrs 62090 semi-coma 10 d PT OT ST 30 d
3 Infertility tmts 99 > 3 u. fibroids > Pills
CN 3 GKRS 52301
IDC 1.2 cm Her2 +++ ER 5% R. Lmptmy SLNB+1 71703 6 FEC 33 R Tamoxifen
Recc IIB 2.5 cm Bi-L Mast 61407 2/9 nds PET
6 TCH Cellulitis - Lymphedema - compression sleeve & glove
H w x 4 MUGA 51 D, J 49 M
Diastasis recti
Tamoxifen B. scan
Irrtbl bowel 1'09
Colonoscopy 313
BRCA1 V1247I
hptc hemangioma
GI - > yogurt
hysterectomy/oophorectomy 011410
Exemestane 25 mg tab 102912 ~ 101016 stopped due to r. hip/l.thigh pain after long walk
DEXA 1/13
1-2016 lesions in liver largest 9mm & 1.3 cm onco. says not cancer.
3-11 Appendectomy - visually O.K., a lot of puss. Final path result - not cancer.
Start Vitamin D3 and Calcium supplement (600mg x2)
10-10 Stopped Exemestane due to r. hip/l.thigh pain OKed by Onco 11-08-2016
7-23-2018 9 mm groundglass nodule within the right lower lobe with indolent behavior. Due to possible adenocarcinoma, Recommend annual surveilence.
7-10-2019 CT to check lung nodule.
1-10-2020 8mm stable nodule on R Lung, two 6mm new ones on L Lung, a possible lymph node involvement in inter fissule.

Advocacy is a passion .. not a pastime - Joe
Jackie07 is offline   Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump

All times are GMT -7. The time now is 01:29 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2023, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter